Akari Therapeutics, Plc (AKTX) Analysts See $-1.00 EPS

March 15, 2018 - By Michael Collier

 Akari Therapeutics, Plc (AKTX) Analysts See $ 1.00 EPS

Analysts expect Akari Therapeutics, Plc (NASDAQ:AKTX) to report $-1.00 EPS on March, 30.They anticipate $0.92 EPS change or 1,150.00 % from last quarter’s $-0.08 EPS. After having $-0.09 EPS previously, Akari Therapeutics, Plc’s analysts see 1,011.11 % EPS growth. The stock increased 1.73% or $0.04 during the last trading session, reaching $2.35. About 24,184 shares traded. Akari Therapeutics, Plc (NASDAQ:AKTX) has declined 48.07% since March 15, 2017 and is downtrending. It has underperformed by 64.77% the S&P500.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company has market cap of $35.85 million. The Company’s lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. It currently has negative earnings. The firm is based in New York, New York.

More news for Akari Therapeutics, Plc (NASDAQ:AKTX) were recently published by: Quotes.Wsj.com, which released: “Akari Therapeutics PLC ADR AKTX (US: Nasdaq)” on September 17, 2015. Marketwatch.com‘s article titled: “Akari Therapeutics PLC ADR” and published on March 30, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: